MedWatch

Pharmacosmos expects massive growth in four years

The company’s new chief executive has ambitions of reaching a DKK 2.5bn (USD 325m) revenue within the time frame.

Tobias S. Christensen (th.) overtog tidligere i år rollen som adm. direktør fra sin far, Lars Christensen (tv.). | Photo: Pharmacosmos / PR

Though Pharmacosmos booked a DKK 1.3bn (USD 169m) revenue and top-line growth of 56% in its last quarterly report, the company’s new chief executive, Tobias Christensen, is setting his sights a little higher, reports Danish business daily Børsen. He expects Pharmacosmos to reach a DKK 2.5bn (USD 325m) revenue within four years, mostly due to the company’s intravenous (IV) iron deficiency treatment, Monofer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs